Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRLD 
Prelude Therapeutics Inc (PRLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PRLD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.23% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 72.45M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 4 | Beta 1.21 | 52 Weeks Range 0.61 - 5.53 | Updated Date 08/29/2025 |
52 Weeks Range 0.61 - 5.53 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.48 | Actual -0.41 |
Profitability
Profit Margin - | Operating Margin (TTM) -1928.67% |
Management Effectiveness
Return on Assets (TTM) -49.75% | Return on Equity (TTM) -96.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17149441 | Price to Sales(TTM) 10.35 |
Enterprise Value 17149441 | Price to Sales(TTM) 10.35 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA -0.54 | Shares Outstanding 43750100 | Shares Floating 29179176 |
Shares Outstanding 43750100 | Shares Floating 29179176 | ||
Percent Insiders 11.34 | Percent Institutions 62.34 |
Upturn AI SWOT
Prelude Therapeutics Inc
Company Overview
History and Background
Prelude Therapeutics Inc. was founded in 2016 and is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting chromatin regulation, an area of cancer biology involved in gene expression control.
Core Business Areas
- PRMT5 Inhibitors: Focuses on developing PRMT5 inhibitors, such as PRT543 and PRT811, for hematologic malignancies and solid tumors.
- SMARCA2 Degrader: Developing a SMARCA2 degrader for specific cancers.
Leadership and Structure
Dr. Kris Vaddi is the CEO. The company has a board of directors and a management team overseeing research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- PRT543: PRT543 is an oral, selective inhibitor of protein arginine methyltransferase 5 (PRMT5) being developed for genetically defined cancers, including solid tumors. The company is focusing on biomarker-selected patients. Competitors include companies developing other PRMT5 inhibitors, such as Novartis and GSK.
- PRT811: PRT811 is an oral, selective PRMT5 inhibitor being developed for hematologic malignancies. Competitors include companies developing other PRMT5 inhibitors, such as Novartis and GSK.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, regulatory hurdles, and intense competition. The market for cancer therapeutics is large and growing, with increasing demand for targeted therapies.
Positioning
Prelude Therapeutics is positioned as a company focused on novel cancer targets and precision medicine. Its competitive advantage lies in its expertise in chromatin regulation and its pipeline of differentiated small molecule inhibitors.
Total Addressable Market (TAM)
The total addressable market for cancer therapeutics is estimated to be hundreds of billions of dollars. Prelude is targeting specific patient populations with unmet needs, aiming for a significant share within its focused areas.
Upturn SWOT Analysis
Strengths
- Novel targets in chromatin regulation
- Pipeline of differentiated small molecule inhibitors
- Experienced management team
- Focus on precision medicine
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on successful clinical trials
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Patent expirations
- Market volatility
Competitors and Market Share
Key Competitors
- GILD
- NVS
- GSK
- MRTX
Competitive Landscape
Prelude Therapeutics competes with large pharmaceutical companies and other biotech companies developing cancer therapies. Its advantage lies in its focus on novel targets and precision medicine, but it faces challenges in competing with companies with greater resources and established commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing preclinical programs into clinical trials and raising capital through public and private offerings.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing PRT543 and PRT811 through clinical trials and exploring new indications for its pipeline candidates.
Summary
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Its strength lies in its focus on chromatin regulation and differentiated small molecule inhibitors. The company is highly dependent on successful clinical trials and faces competition from larger pharmaceutical companies. Investors should watch for clinical trial updates and regulatory milestones.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (estimates)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be estimated and subject to change. Market share data is approximated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prelude Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2020-09-25 | Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://preludetx.com |
Full time employees 131 | Website https://preludetx.com | ||
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.